In a report issued on November 15, Gregory Renza from RBC Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $9.00. The company’s shares closed last Monday at $6.15.
According to TipRanks.com, Renza is a 1-star analyst with an average return of -1.1% and a 30.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Inovio Pharmaceuticals.
BELLUS Health has an analyst consensus of Strong Buy, with a price target consensus of $10.96, representing a 78.8% upside. In a report issued on November 10, BTIG also maintained a Buy rating on the stock with a $13.00 price target.
The company has a one-year high of $7.65 and a one-year low of $2.60. Currently, BELLUS Health has an average volume of 2.24M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Read More on BLU: